BETA Technologies launches IPO of 25 million shares priced $27-$33
Eugene Schneider, Executive Vice President and Chief Clinical Development Officer at IONIS PHARMACEUTICALS (NASDAQ:IONS), a $9.47 billion market cap biotechnology company, sold a total of 19,658 shares of common stock on September 3, 2025, with the transactions valued at $1.19 million. The sale comes as the stock trades near its 52-week high of $62.08, having gained over 75% in the past six months.
The sales were executed in two tranches. The first involved 12,455 shares sold at a weighted average price of $60.4608, with individual prices ranging from $60.1862 to $61.14. The second transaction saw 7,203 shares sold at a weighted average price of $61.4163, with prices ranging from $61.21 to $61.66.
On the same day, Schneider also exercised options to acquire 19,658 shares of IONIS PHARMACEUTICALS stock at a price of $53.77 per share, for a total value of $1057010.
Following these transactions, Schneider directly owns 51,507 shares of IONIS PHARMACEUTICALS INC. Some of the sales were executed under a Rule 10b5-1 trading plan adopted on May 2, 2025.
In other recent news, Ionis Pharmaceuticals has reported significant developments that have drawn attention from analysts and investors alike. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, showing statistically significant benefits in triglyceride lowering and reducing the risk of acute pancreatitis. Following these results, H.C. Wainwright increased its price target for Ionis Pharmaceuticals to $95, maintaining a Buy rating, while noting the substantial triglyceride reductions in the studies. RBC Capital also raised its price target to $80, highlighting the positive Phase III data for the acute pancreatitis treatment. Similarly, Oppenheimer adjusted its price target to $81, maintaining an Outperform rating after the promising trial results for Tryngolza (olezarsen).
BMO Capital upgraded Ionis Pharmaceuticals from Market Perform to Outperform, citing the blockbuster potential of Olezarsen, which exceeded both analyst and investor expectations. The positive outlook on the drug reflects its potential to become a major player in the U.S. market. These analyst actions underline the optimism surrounding Ionis Pharmaceuticals’ recent trial results and their potential impact on future earnings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.